Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2

Stefania Varchetta, Nadia Gibelli, Barbara Oliviero, Elena Nardini, Roberto Gennari, Giovanna Gatti, Luzemira Santos Silva, Laura Villani, Elda Tagliabue, Sylvie Ménard, Alberto Costa, Francesco F. Fagnoni

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Preliminary results from a pilot trial on trastuzumab's mechanism of action against operable breast tumors overexpressing Her2 suggested a role for antibody-dependent cell cytotoxicity (ADCC). To examine factors affecting ADCC intensity and variability, we extended this study to the phenotypic and functional analysis of circulating mononuclear cells in 18 patients. ADCC was induced by trastuzumab therapy in 15 of 18 patients (83%). Inability to develop ADCC in three patients did not depend on inadequate levels of trastuzumab because further increase in its concentration in vitro was ineffective. Rather, susceptibility to develop ADCC was fairly predicted by test with trastuzumab before therapy and was correlated to the number of lymphocytes coexpressing CD16 and CD56. Phenotypic analysis at the end of ADCC evaluating down-regulation of CD16, and up-regulation of CD69 and CD107a, confirmed that natural killer (NK)cel ls and CD56+ T cells were involved in productive engagement of trastuzumab. Also, the killing efficiency of CD16+ lymphocytes was influenced by 158 V/F polymorphism of FcγRIII (CD16), whereas variations of CD247 on NK cells were consistent with trends between ADCC before and after therapy. Complete pathologic response was observed in one patient showing ADCC of outstanding intensity, whereas four cases of partial response showed intermediate ADCC; none of the three patients unable to mount ADCC had significant tumor regression. These data indicate that quantity and lytic efficiency of CD16+ lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.

Original languageEnglish
Pages (from-to)11991-11999
Number of pages9
JournalCancer Research
Volume67
Issue number24
DOIs
Publication statusPublished - Dec 15 2007

Fingerprint

Antibody-Dependent Cell Cytotoxicity
Breast Neoplasms
Therapeutics
Trastuzumab
Lymphocytes
Lymphocyte Count
Natural Killer Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. / Varchetta, Stefania; Gibelli, Nadia; Oliviero, Barbara; Nardini, Elena; Gennari, Roberto; Gatti, Giovanna; Silva, Luzemira Santos; Villani, Laura; Tagliabue, Elda; Ménard, Sylvie; Costa, Alberto; Fagnoni, Francesco F.

In: Cancer Research, Vol. 67, No. 24, 15.12.2007, p. 11991-11999.

Research output: Contribution to journalArticle

Varchetta, Stefania ; Gibelli, Nadia ; Oliviero, Barbara ; Nardini, Elena ; Gennari, Roberto ; Gatti, Giovanna ; Silva, Luzemira Santos ; Villani, Laura ; Tagliabue, Elda ; Ménard, Sylvie ; Costa, Alberto ; Fagnoni, Francesco F. / Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. In: Cancer Research. 2007 ; Vol. 67, No. 24. pp. 11991-11999.
@article{a547be5f579e443a8c168fd3874672d5,
title = "Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2",
abstract = "Preliminary results from a pilot trial on trastuzumab's mechanism of action against operable breast tumors overexpressing Her2 suggested a role for antibody-dependent cell cytotoxicity (ADCC). To examine factors affecting ADCC intensity and variability, we extended this study to the phenotypic and functional analysis of circulating mononuclear cells in 18 patients. ADCC was induced by trastuzumab therapy in 15 of 18 patients (83{\%}). Inability to develop ADCC in three patients did not depend on inadequate levels of trastuzumab because further increase in its concentration in vitro was ineffective. Rather, susceptibility to develop ADCC was fairly predicted by test with trastuzumab before therapy and was correlated to the number of lymphocytes coexpressing CD16 and CD56. Phenotypic analysis at the end of ADCC evaluating down-regulation of CD16, and up-regulation of CD69 and CD107a, confirmed that natural killer (NK)cel ls and CD56+ T cells were involved in productive engagement of trastuzumab. Also, the killing efficiency of CD16+ lymphocytes was influenced by 158 V/F polymorphism of FcγRIII (CD16), whereas variations of CD247 on NK cells were consistent with trends between ADCC before and after therapy. Complete pathologic response was observed in one patient showing ADCC of outstanding intensity, whereas four cases of partial response showed intermediate ADCC; none of the three patients unable to mount ADCC had significant tumor regression. These data indicate that quantity and lytic efficiency of CD16+ lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.",
author = "Stefania Varchetta and Nadia Gibelli and Barbara Oliviero and Elena Nardini and Roberto Gennari and Giovanna Gatti and Silva, {Luzemira Santos} and Laura Villani and Elda Tagliabue and Sylvie M{\'e}nard and Alberto Costa and Fagnoni, {Francesco F.}",
year = "2007",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-07-2068",
language = "English",
volume = "67",
pages = "11991--11999",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2

AU - Varchetta, Stefania

AU - Gibelli, Nadia

AU - Oliviero, Barbara

AU - Nardini, Elena

AU - Gennari, Roberto

AU - Gatti, Giovanna

AU - Silva, Luzemira Santos

AU - Villani, Laura

AU - Tagliabue, Elda

AU - Ménard, Sylvie

AU - Costa, Alberto

AU - Fagnoni, Francesco F.

PY - 2007/12/15

Y1 - 2007/12/15

N2 - Preliminary results from a pilot trial on trastuzumab's mechanism of action against operable breast tumors overexpressing Her2 suggested a role for antibody-dependent cell cytotoxicity (ADCC). To examine factors affecting ADCC intensity and variability, we extended this study to the phenotypic and functional analysis of circulating mononuclear cells in 18 patients. ADCC was induced by trastuzumab therapy in 15 of 18 patients (83%). Inability to develop ADCC in three patients did not depend on inadequate levels of trastuzumab because further increase in its concentration in vitro was ineffective. Rather, susceptibility to develop ADCC was fairly predicted by test with trastuzumab before therapy and was correlated to the number of lymphocytes coexpressing CD16 and CD56. Phenotypic analysis at the end of ADCC evaluating down-regulation of CD16, and up-regulation of CD69 and CD107a, confirmed that natural killer (NK)cel ls and CD56+ T cells were involved in productive engagement of trastuzumab. Also, the killing efficiency of CD16+ lymphocytes was influenced by 158 V/F polymorphism of FcγRIII (CD16), whereas variations of CD247 on NK cells were consistent with trends between ADCC before and after therapy. Complete pathologic response was observed in one patient showing ADCC of outstanding intensity, whereas four cases of partial response showed intermediate ADCC; none of the three patients unable to mount ADCC had significant tumor regression. These data indicate that quantity and lytic efficiency of CD16+ lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.

AB - Preliminary results from a pilot trial on trastuzumab's mechanism of action against operable breast tumors overexpressing Her2 suggested a role for antibody-dependent cell cytotoxicity (ADCC). To examine factors affecting ADCC intensity and variability, we extended this study to the phenotypic and functional analysis of circulating mononuclear cells in 18 patients. ADCC was induced by trastuzumab therapy in 15 of 18 patients (83%). Inability to develop ADCC in three patients did not depend on inadequate levels of trastuzumab because further increase in its concentration in vitro was ineffective. Rather, susceptibility to develop ADCC was fairly predicted by test with trastuzumab before therapy and was correlated to the number of lymphocytes coexpressing CD16 and CD56. Phenotypic analysis at the end of ADCC evaluating down-regulation of CD16, and up-regulation of CD69 and CD107a, confirmed that natural killer (NK)cel ls and CD56+ T cells were involved in productive engagement of trastuzumab. Also, the killing efficiency of CD16+ lymphocytes was influenced by 158 V/F polymorphism of FcγRIII (CD16), whereas variations of CD247 on NK cells were consistent with trends between ADCC before and after therapy. Complete pathologic response was observed in one patient showing ADCC of outstanding intensity, whereas four cases of partial response showed intermediate ADCC; none of the three patients unable to mount ADCC had significant tumor regression. These data indicate that quantity and lytic efficiency of CD16+ lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.

UR - http://www.scopus.com/inward/record.url?scp=37549011436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549011436&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-2068

DO - 10.1158/0008-5472.CAN-07-2068

M3 - Article

VL - 67

SP - 11991

EP - 11999

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 24

ER -